[go: up one dir, main page]

AR052195A1 - Composiciones de patrones moleculares asociados a patogenos en metodos de uso - Google Patents

Composiciones de patrones moleculares asociados a patogenos en metodos de uso

Info

Publication number
AR052195A1
AR052195A1 ARP060100194A AR052195A1 AR 052195 A1 AR052195 A1 AR 052195A1 AR P060100194 A ARP060100194 A AR P060100194A AR 052195 A1 AR052195 A1 AR 052195A1
Authority
AR
Argentina
Prior art keywords
protein
compositions
flavivirus protein
flavivirus
polypeptides
Prior art date
Application number
Other languages
English (en)
Inventor
Thomas J Powell
Valerian Nakaar
Langzhou Song
William F Mcdonald
Duane D Hewitt
James W Huleatt
Original Assignee
Vaxinnate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxinnate Corp filed Critical Vaxinnate Corp
Publication of AR052195A1 publication Critical patent/AR052195A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las composiciones comprenden al menos una porcion de un antígeno y al menos una porcion de una flagelina que carece de una region de bisagra. Composiciones, proteínas de fusion y polipéptidos que comprenden al menos una porcion de al menos un patron molecular asociado a patogenos y al menos una porcion de al menos una proteína viral. La proteína viral de las composiciones, proteínas de fusion y polipéptidos de la presente son proteínas flavivirales, incluyendo una proteína del flavivirus del Nilo Occidental, una proteína del flavivirus de Dengue, una proteína del flavivirus de Langat, una proteína de flavivirus de Kunjin, una proteína del flavivirus de la encefalitis de Murray Valley, una proteína del flavivirus de la encefalitis japonesa, una proteína del flavivirus de la encefalitis transmitida por garrapatas, una proteína el flavivirus de la fiebre amarilla y una proteína del flavivirus de la hepatitis C. Las composiciones, proteínas de fusion y polipéptidos se usan para estimular una respuesta inmune en un sujeto.
ARP060100194 2005-01-19 2006-01-19 Composiciones de patrones moleculares asociados a patogenos en metodos de uso AR052195A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64517005P 2005-01-19 2005-01-19
US65340505P 2005-02-15 2005-02-15
US70416005P 2005-07-29 2005-07-29
US72340905P 2005-10-04 2005-10-04
US72591905P 2005-10-11 2005-10-11

Publications (1)

Publication Number Publication Date
AR052195A1 true AR052195A1 (es) 2007-03-07

Family

ID=36692789

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100194 AR052195A1 (es) 2005-01-19 2006-01-19 Composiciones de patrones moleculares asociados a patogenos en metodos de uso

Country Status (11)

Country Link
US (4) US8574588B2 (es)
EP (2) EP2374474A1 (es)
JP (1) JP2008527009A (es)
AR (1) AR052195A1 (es)
AU (2) AU2006206647C1 (es)
BR (1) BRPI0606479A (es)
CA (1) CA2594612A1 (es)
MY (1) MY157941A (es)
SG (1) SG158894A1 (es)
TW (1) TW200640485A (es)
WO (1) WO2006078657A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
AR052195A1 (es) 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
WO2007078879A2 (en) * 2005-12-21 2007-07-12 Vaxinnate Corporation Lipopeptide compositions and methods of use thereof
CU23630A1 (es) * 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
KR100823866B1 (ko) * 2007-02-09 2008-04-21 전남대학교산학협력단 톨-유사 수용체-5 자극 활성이 증가된 플라젤린 변형체
WO2008097016A1 (en) 2007-02-09 2008-08-14 Chonnam National University Modified flagellin improved toll-like receptor 5 stimulating activity
ES2539818T3 (es) 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Vacunas contra la gripe multiepitópicas multiméricas
WO2009073133A1 (en) * 2007-11-29 2009-06-11 Vaxinnate Corporation Compositions of toll-like receptor agonists and papillomavirus antigens and uses thereof
CA2721246A1 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
EP2278994A4 (en) * 2008-04-25 2012-01-18 Inst Systems Biology Flagellin POLYPEPTIDE VACCINES
WO2009156405A1 (en) * 2008-06-25 2009-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel immunoadjuvant flagellin-based compounds and use thereof
SI22889A (sl) * 2008-10-28 2010-04-30 Kemijski inštitut Himerni flagelini za cepiva
WO2010124212A2 (en) 2009-04-23 2010-10-28 The University Of Chicago Materials and methods for the preparation of nanocomposites
EP2272860A1 (en) * 2009-07-10 2011-01-12 Institut Pasteur Multivalent epitope in complex with a detection marker for the early serodiagnosis of infections
CN104136614B (zh) * 2009-10-06 2018-04-06 帕纳塞拉实验室有限责任公司 Toll‑样受体和激动剂用于治疗癌症的用途
US10080799B2 (en) * 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
US8993744B2 (en) 2010-05-21 2015-03-31 University of Pittsburgh—of the Commonwealth System of Higher Education Universal dengue virus sequences and methods of use
WO2012045063A2 (en) * 2010-10-01 2012-04-05 University Of Rochester Flavivirus domain iii vaccine
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EP2681246A4 (en) * 2011-02-28 2015-05-06 Vaxinnate Corp VACCINE AGAINST DENGUE TATRAVALENT AND MIXED BIVALENT
KR101814558B1 (ko) * 2011-07-05 2018-01-30 수저우 시스케이프 바이오메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 염증성 장 질환을 예방 및 치료하기 위한 약물 제조에 있어 살모넬라 플라젤린 유도체의 용도
CA2875391A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
JP6086378B2 (ja) * 2012-11-30 2017-03-01 国立大学法人お茶の水女子大学 組み換えヒト膵臓リパーゼの調製方法
US20170051021A1 (en) * 2014-04-30 2017-02-23 Vinca Institute Of Nuclear Sciences Peptide agonists of toll-like receptor 5 ligand and method of use
CN109310741A (zh) * 2016-04-29 2019-02-05 阿拉伊姆药品公司 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽
TWI625393B (zh) * 2016-11-15 2018-06-01 國立清華大學 對抗複數種登革熱病毒血清型之疫苗套組及其製備方法與用途
CN111892648B (zh) * 2020-06-08 2022-08-26 中国科学院上海药物研究所 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用
CN114231496B (zh) * 2021-11-30 2023-05-26 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 马流产沙门氏菌竞争elisa抗体检测试剂盒及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666839A (en) * 1982-12-01 1987-05-19 Amgen Methods and materials for obtaining microbial expression of polypeptides including bovine prolactin
US5817753A (en) * 1985-12-04 1998-10-06 The Ohio State University Research Foundation Antigenic modification of polypeptides
NZ219516A (en) 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
AU637049B2 (en) * 1988-05-05 1993-05-20 American Cyanamid Company Recombinant flagellin vaccines
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5976552A (en) 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
US5895651A (en) * 1996-06-27 1999-04-20 The United States Of America As Represented By The Secretary Of The Navy Recombinant dengue virus envelope protein/maltose-binding protein antigens and subunit vaccine compositions containing said antigens
ES2258796T3 (es) 1996-11-26 2006-09-01 Stressgen Biotechnologies Corporation Proteinas de fusion que contienen proteinas de estres para inducir respuestas inmunitarias.
GB9625283D0 (en) * 1996-12-04 1997-01-22 Janssen Pharmaceutica Nv Vertebrate homologues of unc-53 protein of c.elegans or functional eqivalents thereof and cdna sequences coding for said homologue
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6730778B2 (en) * 1997-12-19 2004-05-04 Pharmacia And Upjohn Company Human sel-10 polypeptides and polynucleotides that encode them
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU4709401A (en) * 1999-11-29 2001-06-12 Inotek Corporation Composition and method for treating a microbial infection
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
CA2418036A1 (en) 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
AU1252102A (en) * 2000-11-07 2002-05-21 Paradigm Therapeutics Ltd Receptor
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
DE60141773D1 (de) * 2001-04-20 2010-05-20 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
WO2004035784A2 (en) * 2002-10-21 2004-04-29 Rna-Line Oy Soluble rna polymerase protein and methods for the use thereof
WO2005042564A1 (en) * 2003-10-20 2005-05-12 Sidney Kimmel Cancer Center Flagellin fusion proteins as adjuvants or vaccines and methods of use
CA2555253A1 (en) * 2004-02-06 2005-08-25 Yale University Compositions of pamps and listeria monocytogenes and methods of use
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
JP2008523818A (ja) * 2004-12-16 2008-07-10 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 腫瘍免疫療法におけるフラジェリンの使用
US8420102B2 (en) * 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
BRPI0519705A2 (pt) * 2004-12-21 2009-03-10 Vaxinnate Corp composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
HU227285B1 (en) 2004-12-29 2011-01-28 Mta Enzimologiai Intezet Modified flagellins and flagellar filaments useful as receptors and processes for producing same
AR052195A1 (es) 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
EP2010572B1 (en) 2006-04-19 2013-10-23 POSTECH Academy-Industry Foundation Fusion proteins comprising hpv polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer
US20100015170A1 (en) * 2006-07-21 2010-01-21 Fumihiko Takeshita Flagellin mutant vaccine
ES2539818T3 (es) 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Vacunas contra la gripe multiepitópicas multiméricas
WO2009073133A1 (en) 2007-11-29 2009-06-11 Vaxinnate Corporation Compositions of toll-like receptor agonists and papillomavirus antigens and uses thereof
CA2721246A1 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
EP2278994A4 (en) 2008-04-25 2012-01-18 Inst Systems Biology Flagellin POLYPEPTIDE VACCINES
WO2011084967A2 (en) 2010-01-06 2011-07-14 Vaxinnate Corporation Methods and compositions for providing protective immunity in the elderly
WO2012115715A2 (en) 2011-02-21 2012-08-30 Vaxinnate Corporation Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use
EP2681246A4 (en) 2011-02-28 2015-05-06 Vaxinnate Corp VACCINE AGAINST DENGUE TATRAVALENT AND MIXED BIVALENT
WO2013065365A1 (ja) 2011-11-01 2013-05-10 オリンパスメディカルシステムズ株式会社 超音波振動子エレメントおよび超音波内視鏡
WO2013066365A1 (en) 2011-11-04 2013-05-10 Vaxinnate Corporation Immunologic constructs and methods
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
WO2014130938A1 (en) 2013-02-25 2014-08-28 Vaxinnate Corporation Particle formulations for delivery of tlr agonists and antigens
WO2014168948A2 (en) 2013-04-09 2014-10-16 Vaxinnate Corporation Clostridium difficile compositions and methods of use

Also Published As

Publication number Publication date
MY157941A (en) 2016-08-15
AU2006206647B9 (en) 2010-11-04
US8871221B2 (en) 2014-10-28
US20150031858A1 (en) 2015-01-29
EP1841785A2 (en) 2007-10-10
US9446115B2 (en) 2016-09-20
AU2006206647A1 (en) 2006-07-27
SG158894A1 (en) 2010-02-26
AU2006206647B2 (en) 2010-08-12
TW200640485A (en) 2006-12-01
AU2006206647C1 (en) 2011-01-20
JP2008527009A (ja) 2008-07-24
BRPI0606479A (pt) 2008-03-11
US20160158338A1 (en) 2016-06-09
CA2594612A1 (en) 2006-07-27
US9234009B2 (en) 2016-01-12
US20080063657A1 (en) 2008-03-13
AU2010233052A1 (en) 2010-11-04
EP2374474A1 (en) 2011-10-12
WO2006078657A3 (en) 2007-06-21
WO2006078657A2 (en) 2006-07-27
US20140037683A1 (en) 2014-02-06
US8574588B2 (en) 2013-11-05

Similar Documents

Publication Publication Date Title
AR052195A1 (es) Composiciones de patrones moleculares asociados a patogenos en metodos de uso
Gerold et al. Protein interactions during the flavivirus and hepacivirus life cycle
DE602005026545D1 (de) Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
Kaufmann et al. Molecular mechanisms involved in the early steps of flavivirus cell entry
Srikiatkhachorn et al. Endothelial cells in dengue hemorrhagic fever
SG165155A1 (en) Novel flavivirus antigens
CO6141481A2 (es) Flavirus seudoinfecciosos y usos de los mismos
SG160424A1 (en) Compositions of influenza viral proteins and methods of use thereof
DK2450373T3 (da) Rekombinante humane epo-fc-fusionsproteiner med forlænget halveringstid og forstærket erythropoietisk aktivitet in vivo
BRPI0507118A (pt) polipeptìdeos de interferon humano modificado e seus usos
DE69230316D1 (de) Chimäre und/oder wachstumsgehemmte flaviviren
JP2008520187A5 (es)
ES2387141T8 (es) Composición que comprende la poliproteína NS3/NS4 y el polipéptido NS5b del VHC, vectores de expresión que incluyen las secuencias nucleicas correspondientes y su utilización terapéutica
DK1949913T3 (da) Immunstimulatorisk kombination til profylakserne og behandlingen af hepatitis C
ATE461453T1 (de) Nukleinsäuresequenz und protein, das eine rolle bei der zellulären alterung spielt
WO2006121467A3 (en) Tetrahydrocarbazole derivatives for treating flaviridae viruses
BRPI0401908A (pt) Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses
WO2011084604A3 (en) Flavivirus species-specific peptide tags for vaccine and diagnostic use
DE602004000237D1 (de) Bahnenmaterial, Ball vom mit Gas befüllbaren Typ und Handschuh
ITMI20041675A1 (it) Blocco di commutazione e relativa matrice di commutazione, in particolare per architetture fpga.
EP1840214A4 (en) DEFICIENT CHIMERIC FLAVIVIRUS WITH WEAKENED JAPANESE ENZEPHALITIS VIRUS GENE AS BASIC EQUIPMENT
WO2007035530A3 (en) Ancestral dengue virus envelope protein sequence
ATE430167T1 (de) Humaner rekombinanter antikörper gegen das hepatitis c (hcv) nichtstrukturelles ns3 protein, nukleinsäure und deren verwendungen
Deubel Molecular characterization of Japanese encephalitis virus NS1 protein
AR051851A1 (es) Composiciones de proteinas de virus de gripe y metodo de uso de las mismas

Legal Events

Date Code Title Description
FB Suspension of granting procedure